|
Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort. |
|
|
Consulting or Advisory Role - Bio-Path Holdings, Inc; Gilead Sciences; Novartis; Pfizer; Rigel; Sun Pharma; Takeda; Terns Pharmaceuticals |
Research Funding - Abbvie/Genentech (Inst); Actuate Therapeutics (Inst); Bio-Path Holdings, Inc (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Sellas Life Sciences (Inst); Sun Pharma (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - Abbvie; BMS; Daiichi Sankyo; Genentech; Gilead Sciences; GlycoMimetics; Kura Oncology; Kymera; Rigel; Servier; Syndax |
Research Funding - Abbvie (Inst); Amgen (Inst); Aptose Biosciences (Inst); AROG (Inst); Biomea Fusion (Inst); BMS (Inst); Celgene (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immune-Onc Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kymera (Inst); Loxo (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Treadwell Therapeutics (Inst) |
Travel, Accommodations, Expenses - Rigel |
Other Relationship - Gilead Sciences; GlycoMimetics |
|
|
Consulting or Advisory Role - Aptose Biosciences; Astellas Pharma; Celgene/Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Rafael Pharmaceuticals; Reven Pharmaceuticals; Rigel; SERVIER; Takeda |
Research Funding - Immune System Key; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Agios; Astellas Pharma; Bayer; Celgene; Daiichi Sankyo; Forma Therapeutics; Janssen; Seagen; Syros Pharmaceuticals |
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Bayer; Celgene; Daiichi Sankyo; Janssen; Novartis; Pfizer; Pierre Fabre; SERVIER; Syros Pharmaceuticals |
Speakers' Bureau - Celgene |
Research Funding - Agios; Forma Therapeutics |